Frailty (geriatric exhaustion) is a common condition in adults over 70: weight loss, general weakness, slowness of walking, and constant fatigue. To date, there is no specific treatment. Only nutritional advice and physiotherapy. But a new study published in Cell Stem Cell by the Longeveron company presents the news: mesenchymal stem cell therapy can reverse frailty. And not just slow it down.
The experiment
The team recruited 148 ambulatory elderly (that is, able to walk on their own) diagnosed with frailty. They were divided into a treatment group and a placebo group, and received intravenous injections of allogeneic mesenchymal stem cells (donated from bone marrow of healthy donors). These cells, called laromestrocel, are cells that know how to suppress inflammation and release growth factors.
The results after 9 months
The team measured physical ability using the 6-minute walk test (6MWT), a standard test in geriatrics:
- The treated group showed an improvement of 63.4 meters in walking during 6 minutes
- The control group showed negligible improvement
- 30.8% of patients changed from frail to non-frail status
This difference is not just statistical. 63 meters in 6 minutes is the difference between those who can get down and up from first place and those who can't. This is the difference between independence and dependence.
How does it work?
Allogeneic mesenchymal stem cells work by several parallel mechanisms:
- inflammaging suppression. They secrete anti-inflammatory factors that reduce the chronic inflammatory background that characterizes aging
- Vascular function correction. They improve blood vessel function, which improves oxygen flow to the muscles
- muscle rehabilitation. They stimulate satellite cells in the muscle, which lead to rebuilding
- Endocrine signaling. They improve the hormones related to body health, such as IGF-1
The advantage of "allogeneic"
"Allogeneic" means that the stem cells come from a donor's bone marrow, not from the patient himself. This is a great advantage in terms of availability: the treatment can be produced in advance and used in a wide variety of patients. No need to wait for personal processing. In addition, MSC cells are considered "immune-privileged", that is, they do not trigger a rejection reaction.
What next?
The company is planning a larger Phase 3 trial in 2027. If the results hold, laromestrocel could be the first treatment specifically approved for healthy aging. Meanwhile, several companies (mainly in the US, Japan and Korea) offer similar treatments outside of a regulatory clinic. The researchers warn: Stem cell treatments are only approved in clinical trials. Any commercial treatment is considered unapproved and can be dangerous.
The bottom line
This is the first large-scale trial to show that stem cell therapy can reverse frailty, not just slow it down. This is a big step towards active aging: not only living more years, but living them with strength and normal function.
💬 תגובות (0)
היו הראשונים להגיב על המאמר.